January Therapeutics
Mark Foletta is on the Board of Advisors at January Therapeutics. Mark is also the Board Member at Dexcom.
This person is not in the org chart
January Therapeutics
January Therapeutics is developing next generation targeted anti-cancer therapies. Building upon the finding that protein-based nano-formulations have led to substantial improvements in the efficacy of known drugs, January is developing unique chemical matter to leverage well established anti-cancer mechanisms of action while adding new cancer targeting properties.